InsiderClue
Stocks · Health care · Pharmaceutical Preparations

CytoMed Therapeutics Ltd

GDTC Clue Score62
Singapore Fiscal year ends December CIK 0001873093
$0.81 -8.83% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.81 −77.04% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 14 Apr 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueNet income
Fiscal year 2020Net income−1.9EPS, diluted−0.33Fiscal year 2021Net income−2.1EPS, diluted−0.30Fiscal year 2022Net income−3.1EPS, diluted−0.40Fiscal year 2023Net income−4.1EPS, diluted−0.39Fiscal year 2024Revenue0.1Net income−2.5EPS, diluted−0.22Fiscal year 2025Revenue0.3 +366.7%Net income−4.0EPS, diluted−0.34
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a 0.1 0.3
Growth +366.7%
Net income −1.9 −2.1 −3.1 −4.1 −2.5 −4.0
Growth
EPS, diluted −0.33 −0.30 −0.40 −0.39 −0.22 −0.34
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Net margin
Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Net margin−3,621.1%Free cash flow margin−5,913.8%Fiscal year 2025Net margin−1,227.1%Free cash flow margin−1,336.5%
FY2020FY2021FY2022FY2023FY2024FY2025
Net margin n/a n/a n/a n/a −3,621.1% −1,227.1%
Free cash flow margin n/a n/a n/a n/a −5,913.8% −1,336.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−0.8Capital expenditure−0.2Free cash flow−1.1Fiscal year 2021Operating cash flow−1.7Capital expenditure−0.6Free cash flow−2.3Fiscal year 2022Operating cash flow−1.4Capital expenditure−0.5Free cash flow−1.9Fiscal year 2023Operating cash flow−3.5Capital expenditure−0.1Free cash flow−3.6Fiscal year 2024Operating cash flow−2.7Capital expenditure−1.4Free cash flow−4.1Fiscal year 2025Operating cash flow−3.7Capital expenditure−0.6Free cash flow−4.3
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.8 −1.7 −1.4 −3.5 −2.7 −3.7
Capital expenditure −0.2 −0.6 −0.5 −0.1 −1.4 −0.6
Free cash flow −1.1 −2.3 −1.9 −3.6 −4.1 −4.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash0.9Shareholders’ equity0.5Fiscal year 2021Cash2.5Total debt0.5Net cash (debt)2.0Shareholders’ equity2.6Debt to equity0.21Fiscal year 2022Cash1.6Total debt0.5Net cash (debt)1.1Shareholders’ equity0.6Debt to equity0.80Fiscal year 2023Cash6.2Total debt0.4Net cash (debt)5.8Shareholders’ equity11.2Debt to equity0.04Fiscal year 2024Cash4.7Total debt0.4Net cash (debt)4.3Shareholders’ equity9.0Debt to equity0.04Fiscal year 2025Cash2.1Total debt0.4Net cash (debt)1.7Shareholders’ equity6.5Debt to equity0.06
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.9 2.5 1.6 6.2 4.7 2.1
Total debt n/a 0.5 0.5 0.4 0.4 0.4
Net cash (debt) n/a 2.0 1.1 5.8 4.3 1.7
Shareholders’ equity 0.5 2.6 0.6 11.2 9.0 6.5
Debt to equity n/a 0.21 0.80 0.04 0.04 0.06

In millions of SGD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of SGD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a n/a n/a 0.1 0.3
Growth +366.7%
1.0 1.1 1.5 1.6 1.9 2.2
−1.9 −2.1 −3.1 −4.1 −2.5 −4.0
n/a n/a 0.0 0.0 n/a n/a
−1.9 −2.1 −3.1 −4.1 −2.5 −4.0
Growth
Per share
n/a −0.30 −0.40 −0.39 −0.22 −0.34
−0.33 −0.30 −0.40 −0.39 −0.22 −0.34
Growth
n/a 6.9 7.9 10.6 11.5 11.6
5.9 6.9 7.9 10.6 11.5 11.6
Growth +17.6% +14.1% +34.3% +8.6% +0.9%

Shown in SGD as filed; the screener converts to dollars.

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 97.5% in five years, which is dilution.
  • A net loss in 6 of 6 years on file.